Novartis AG
TUMOR MUTATION BURDEN ALONE OR IN COMBINATION WITH IMMUNE MARKERS AS BIOMARKERS FOR PREDICTING RESPONSE TO TARGETED THERAPY

Abstract:

The invention relates to the use of biomarkers for predicting the response to cancer (e.g. melanoma) treatments, for selecting a treatment for a cancer patient (e.g. using targeted therapy, e.g. using a BRAF and/or MEK inhibitor), for stratifying cancer patients into different treatment groups, for treating cancer patients, and for predicting clinical outcome in cancer.